EN DE
Watch InterCure Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

InterCure Ltd. (INCR) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of InterCure Ltd. stock $10.06, price $3.63, upside +177.1%, quality 57 out of 100. Rating: strongly undervalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Israel · ISIN IL0011063760

IL InterCure Ltd. logo Thin data Nov 15, 2026

InterCure Ltd.

INCR · US

Cheap (64% below fair value) and solid company, but falling price: meets 2 of 3 rules.

Get notified free when this changes
Fair value $10.06 · Strongly undervalued 
Low debt 
Generates free cash flow 
Even on cautious assumptions the value is 65% above the price ($6.00). 
Quality 57/100 
Mixed Growth (revenue 5y +33.0 %/yr in ILS) 
Mixed vs. peers (6/11) 
Falling price (downtrend) 
Loss-making · -13.2% net margin (TTM) 
Narrow moat 16/100 · thin data
Thin data 
Watch InterCure Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$43.30 $3.30 Fair Value $10.06 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range $3.30 – $43.30 · fair‑value band $6.00 – $17.97 · the $3.63 price screens below the $10.06 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow InterCure in your weekly email

Every Wednesday you see whether InterCure is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.

Show moreShow less

It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Stock analysis

InterCure Ltd. (INCR) currently trades at $3.63, while our model-based Fair Value estimate is $10.06, implying the stock looks roughly 64% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $9.95 per share, and 8 of the 11 models we run sit above the $3.63 price.

Bear case: the Multiples group reads lowest at $4.06, and 3 of the 11 models stay below the price. Data coverage for this calculation is low.

Scenario range: $6.00 (bear) to $17.97 (bull), the price of $3.63 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2012: revenue and profit before it include the divested business. Growth is measured afresh from 2012.

InterCure Ltd. reported revenue of 270M ILS in FY2025 versus 220M ILS in FY2021, a compound +5.3%/yr. Reported net income was −35.7M ILS in FY2025.

Key figures

Market cap $54.5M Micro · P/S ratio 0.28 · EPS (TTM) $−0.9500 · Net margin −13.2% · Return on equity −9.3% · Return on assets (EBIT) −0.7% (5-year average) · Revenue (TTM) 243M ILS · Revenue growth (YoY) +23.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (low confidence).

What moves the price

The share trades about 50% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at 177%, INCR screens cheaper than that median.

Fair Value models

Bear $6.00 Fair Value $10.06 Bull $17.97
Price $3.63 · Upside +177.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $7.94 $11.51 $22.07 75
EPV $0.6900 $0.8100 $0.9100 74
Growth DCF $7.41 $12.64 $20.81 74
All 12 models by family
DCF Models
FCF DCF $7.94 $11.51 $22.07 75
5Y Revenue Exit $3.38 $4.78 $7.62 69
5Y EBITDA Exit $5.94 $9.95 $17.78 70
10Y Revenue Exit $4.94 $8.27 $9.54 66
10Y EBITDA Exit $6.65 $13.17 $23.94 63
Earnings-Based
EPV $0.6900 $0.8100 $0.9100 74
Multiples
EV/EBIT n/a n/a $0.1300 61
EV/EBITDA $2.35 $4.06 $5.78 65
Asset-Based
NCAV (Graham) $0.3100 $0.4700 $0.5800 55
Growth DCF
Growth DCF $7.41 $12.64 $20.81 74
Rev-Margin DCF $3.61 $5.53 $9.47 68
Economic Profit
ROIC Compounder $0.6900 $0.8100 $0.9100 70

Open the full fair value analysis →

Quality Score breakdown

Overall quality 57/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 77
Are margins and returns getting better?
Cashflow 46
Do the profits arrive as real cash?
Financial strength 38
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 45
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2012: revenue and profit before it include the divested business. Growth is measured afresh from 2012.
Revenue growth 1 year
+13.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.0%
Start year 2020 (pandemic). Over 10 years: +69.2% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−38.3% (2019) → −28.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in ILS, Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about +9.1% a year for the price.

Watch INCR, get fair value alerts →

Compare InterCure Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks

Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 57 · Above median
Fair Value upside +177.1% · Top 25%
Profitability
Return on assets −5.2% · Bottom 25%
Net margin (12 months) −13.2% · Bottom 25%
Operating margin (12 months) 2.5% · Below median
Growth and dividend
Revenue growth (quarter YoY) 23.9% · Top 25%
Balance sheet
Debt / equity 0.15× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.45× · Cheapest 25%
P/S (12 months) 0.73× · Cheapest 25%
Price / free cash flow (fiscal year) 13.3× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 19
FUTURE (revenue growth)100 · sector 28
PAST (return on equity)0 · sector 26
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $84.39 $113.53 +35% vs INCR
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.66 ¥53.04 +11% vs INCR
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,870 ₹1,983 +6% vs INCR
Haleon plc HLN $9.20 $8.47 −8% vs INCR
Merck KGaA MRK €150.75 €108.83 −28% vs INCR
Galderma Group GALD CHF 187.15 CHF 112.46 −40% vs INCR
Takeda Pharmaceutical Company TAK $21.59 $11.23 −48% vs INCR
Sandoz Group SDZ CHF 83.00 CHF 40.54 −51% vs INCR
Teva Pharmaceutical Industries Limited TEVA $42.57 $20.74 −51% vs INCR
Divi's Laboratories Limited DIVISLAB ₹11,150 ₹1,567 −86% vs INCR

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

InterCure Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "InterCure Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/INCR

Frequently asked questions

Is InterCure Ltd. (INCR) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of $10.06 versus a price of $3.63, about +177% upside (undervalued).
What is the fair value of INCR?
Our model-based fair value for InterCure Ltd. is $10.06 (as of Nov 15, 2026), built from audited fundamentals. The current price: $3.63.
What is the quality score of INCR?
InterCure Ltd. has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for InterCure Ltd. (INCR)?
Our model-based price target is the fair value of $10.06 (as of Nov 15, 2026) from 12 valuation models. Cautious scenario $6.00, optimistic scenario $17.97. It is a calculation from audited fundamentals, not an analyst target.
What is the InterCure Ltd. stock forecast for 2026?
Our models put fair value at $10.06, about +177% upside versus a price of $3.63 (undervalued). Cautious scenario $6.00, optimistic scenario $17.97. The calculation is refreshed regularly with new filings.
What is the revenue of InterCure Ltd. (INCR)?
InterCure Ltd. reported trailing-twelve-month revenue of about 243M ILS (latest available figure, as of Nov 15, 2026).
What growth is priced into InterCure Ltd. (INCR)?
For today's price to be fair in a discounted-cash-flow model, InterCure Ltd. would have to grow free cash flow by 11.4 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 33.0 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of INCR use?
Our models discount InterCure Ltd. at 11.6 %: a base by market capitalisation (micro), damped by beta 0.64, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For InterCure Ltd. that is +11.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has InterCure Ltd. (INCR) delivered so far?
Over the past 5 years revenue at InterCure Ltd. grew 33.0 % a year. The price currently implies free-cash-flow growth of +11.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of InterCure Ltd. (INCR) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into InterCure Ltd. (+11.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of InterCure Ltd. (INCR)?
The free-cash-flow yield on the price is 11.13 %: that much free cash flow InterCure Ltd. produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of InterCure Ltd. (INCR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For InterCure Ltd. it is $10.06 per share (as of Nov 15, 2026), against a price of $3.63. It is the blended result of 12 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is InterCure Ltd. stock overvalued or undervalued in 2026?
As of Nov 15, 2026, INCR trades below its calculated fair value: price $3.63, fair value $10.06, a gap of about +177% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INCR?
No. The price is what the market pays today ($3.63); the fair value is what the company's own numbers justify ($10.06). For InterCure Ltd. the two are $6.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is InterCure Ltd. worth?
The market values InterCure Ltd. at about $54.5M (market capitalisation, as of Nov 15, 2026). Per share that is $3.63; our models calculate a fair value of $10.06 per share.
What do the bullish and bearish scenarios say about INCR?
Our models span a range for InterCure Ltd.: cautious scenario $6.00, base $10.06, optimistic $17.97 per share (as of Nov 15, 2026, price $3.63). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of InterCure Ltd. (INCR)?
Balance-sheet figures for InterCure Ltd. (as of Nov 15, 2026): return on equity −9.3%, debt of 0.15 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is INCR from its 52-week high?
InterCure Ltd. trades at $3.63, about 50% below its 52-week high of $7.25 and 10% above the low of $3.30 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $10.06 is for.
Which stocks are comparable to InterCure Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is InterCure Ltd. stock attractive at the current price?
The data as of Nov 15, 2026: price $3.63, calculated fair value $10.06 (+177%), Quality Score 57/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INCR calculated?
We run InterCure Ltd. through 12 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of $10.06 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. InterCure Ltd. currently trades 64% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of InterCure Ltd. (INCR)?
The closing price on Nov 16, 2026 was $3.63. Our model-based fair value is $10.06, about +177% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with InterCure Ltd. right now?
The price is below even our cautious bear case ($6.00). The market is more pessimistic than our downside scenario. The model range is unusually wide ($6.00 to $17.97). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of InterCure Ltd.

How large is the market capitalisation of InterCure Ltd. (INCR)?
The market capitalisation of InterCure Ltd. is $54.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of InterCure Ltd. (INCR)?
The price-to-sales ratio of InterCure Ltd. is 0.28 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of InterCure Ltd. (INCR)?
Earnings per share at InterCure Ltd. are $−0.9500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of InterCure Ltd. (INCR)?
The net margin of InterCure Ltd. is −13.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of InterCure Ltd. (INCR)?
The return on equity (ROE) of InterCure Ltd. is −9.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of InterCure Ltd. (INCR)?
On an EBIT basis the return on assets of InterCure Ltd. is −0.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at InterCure Ltd. (INCR)?
Revenue at InterCure Ltd. is growing 23.9% versus a year earlier (3y avg −11.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at InterCure Ltd. (INCR)?
Earnings per share at InterCure Ltd. are down 84.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does InterCure Ltd. (INCR) carry?
The net debt of InterCure Ltd. is 137M ILS (fiscal year 2025, ≈ 10.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch InterCure Ltd. in the live analysis

One click puts InterCure Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.